A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate

被引：0
|
作者：
Milan Zdravkovic
Anette K. Olsen
Tina Christiansen
Rainer Schulz
Mitchell E. Taub
Mikael S. Thomsen
Michael H. Rasmussen
Mapoko M. Ilondo
机构：
[1] Research and Development,Novo Nordisk A/S
[2] Department of Clinical Drug Development,Novo Nordisk A/S
[3] Quintiles Innovex (Biodesign),undefined
来源：
European Journal of Clinical Pharmacology | 2003年 / 58卷
关键词：
CYP3A4; Interaction; Midazolam; NN703; Clinical study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：683 / 688
页数：5
相关论文
共 50 条
  • [21] Pioglitazone: Effect on CYP3A4 activity
    Nowak, SN
    Edwards, DJ
    Clarke, A
    Anderson, GD
    Jaber, LA
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (12): : 1299 - 1302
  • [22] Discovery of a Highly Selective CYP3A4 Inhibitor Suitable for Reaction Phenotyping Studies and Differentiation of CYP3A4 and CYP3A5
    Li, Xiaohai
    Song, Xinyi
    Kamenecka, Theodore M.
    Cameron, Michael D.
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (09) : 1803 - 1809
  • [23] EFFECT OF DILTIAZEM, A MODERATE CYP3A4 INHIBITOR, ON THE PHARMACOKINETIC PARAMETERS OF TAMSULOSIN
    Lee, Y.
    Byeon, J. Y.
    Kim, Y. H.
    Kim, S. H.
    Lee, H. J.
    Lee, Y. J.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E61 - E62
  • [24] Cisapride (CIS): A potential model substrate to assess CYP3A4 activity.
    Kearns, GL
    Lowry, J
    Khan, I
    Kashuba, A
    Bertino, J
    Nafziger, A
    Abdel-Rahman, S
    Leeder, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P104 - P104
  • [25] Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver
    Watanabe, M
    Kumai, T
    Matsumoto, N
    Tanaka, M
    Suzuki, S
    Satoh, T
    Kobayashi, S
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 (04) : 459 - 462
  • [26] Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity
    Westlind-Johnsson, A
    Hermann, R
    Huennemeyer, A
    Hauns, B
    Lahu, G
    Nassr, N
    Zech, K
    Ingelman-Sundberg, M
    von Richter, O
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) : 339 - 349
  • [27] Domperidone as a substrate marker drug for CYP3A4 and CYP3A5.
    Michaud, V
    Simard, C
    Morin, N
    Turgeon, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P47 - P47
  • [28] Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism
    Collins, Joseph M.
    Wang, Danxin
    PHARMACOGENETICS AND GENOMICS, 2022, 32 (01): : 16 - 23
  • [29] Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide
    Kajosaari, LI
    Jaakkola, T
    Neuvonen, PJ
    Backman, JT
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (03) : 217 - 223
  • [30] Propafenone interaction with CYP3A4 inhibitors in man
    Munoz, CE
    Ito, S
    Bend, JR
    Tesoro, A
    Freeman, D
    Spence, JD
    Bailey, DG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PI69 - PI69
12345